Systemic chemotherapy for patients with bladder cancer - current controversies and future directions

被引:30
|
作者
Chester, JD
Hall, GD
Forster, M
Protheroe, AS
机构
[1] St James Univ Hosp, Canc Res UK Clin Ctr Leeds, Leeds LS9 7TF, W Yorkshire, England
[2] Churchill Hosp, Canc Res UK Med Oncol Unit, Oxford OX3 7LJ, England
关键词
bladder cancer; chemotherapy; cisptatin; gemcitabine; biological therapy; gene therapy;
D O I
10.1016/j.ctrv.2003.12.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many localised, superficial bladder cancers can be effectively controlled. However, disease which has spread to nodes outside the pelvis or to distant organs is generally incurable and systemic therapies, rather than surgery, are appropriate. Combination chemotherapy based around established cytotoxic drugs such as cisplatin has proven benefit in palliating symptoms and prolonging survival in responsive patients with advanced disease. Combination chemotherapies which include newer cytotoxic drugs such as gemcitabine provide the potential for equivalent efficacy with less toxicity than established regimens. Between the extremes of superficial and advanced disease, muscle-invasive bladder cancers have traditionally been treated, with curative intent, by radical surgery or radiotherapy. However, newly published data suggest, for the first time, genuine survival benefits from peri-operative chemotherapy. This article reviews the evidence for cisplatin-based chemotherapy in advanced disease, assesses the potential benefits of newer cytotoxic drugs, discusses the latest evidence pertaining to peri-operative chemotherapy in muscle-invasive disease, and looks forward to potential new biological agents in the systemic therapy of bladder cancer. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:343 / 358
页数:16
相关论文
共 50 条
  • [11] Watch and wait approach in rectal cancer: Current controversies and future directions
    Lopez-Campos, Fernando
    Martin-Martin, Margarita
    Fornell-Perez, Roberto
    Carlos Garcia-Perez, Juan
    Die-Trill, Javier
    Fuentes-Mateos, Raquel
    Lopez-Duran, Sergio
    Dominguez-Rullan, Jose
    Ferreiro, Reyes
    Riquelme-Oliveira, Alejandro
    Hervas-Moron, Asuncion
    Counago, Felipe
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (29)
  • [12] Rotavirus vaccines: Current controversies and future directions
    Coffin S.E.
    Current Infectious Disease Reports, 2000, 2 (1) : 68 - 72
  • [13] Chemotherapy in advanced bladder cancer: current status and future
    Ismaili, Nabil
    Amzerin, Mounia
    Flechon, Aude
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2011, 4
  • [14] Chemotherapy in advanced bladder cancer: current status and future
    Nabil Ismaili
    Mounia Amzerin
    Aude Flechon
    Journal of Hematology & Oncology, 4
  • [15] Advanced/metastatic bladder cancer: current status and future directions
    Facchini, G.
    Cavaliere, C.
    Romis, L.
    Mordente, S.
    Facchini, S.
    Iovane, G.
    Capasso, M.
    D'Errico, D.
    Liguori, C.
    Formato, R.
    Cicala, S.
    Andreozzi, F.
    Di Lauro, G.
    Imbimbo, C.
    Vanni, M.
    D'Aniello, C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (22) : 11536 - 11552
  • [16] NEOADJUVANT CHEMOTHERAPY FOR INVASIVE BLADDER-CANCER - FUTURE-DIRECTIONS
    SCHER, HI
    SPLINTER, TAW
    SEMINARS IN ONCOLOGY, 1990, 17 (05) : 635 - 638
  • [17] Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
    Counago, Felipe
    Luna, Javier
    Leonardo Guerrero, Luis
    Vaquero, Blanca
    Cecilia Guillen-Sacoto, Maria
    Gonzalez-Merino, Teresa
    Taboada, Begona
    Diaz, Veronica
    Rubio-Viqueira, Belen
    Aurora Diaz-Gavela, Ana
    Jose Marcos, Francisco
    del Cerro, Elia
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2019, 10 (10): : 318 - 339
  • [18] Chemotherapy of advanced ovarian cancer: Current status and future directions
    Ozols, RF
    Vermorken, JB
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S1 - S9
  • [19] CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
    Spring, Laura M.
    Wander, Seth A.
    Zangardi, Mark
    Bardia, Aditya
    CURRENT ONCOLOGY REPORTS, 2019, 21 (03)
  • [20] CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
    Laura M. Spring
    Seth A. Wander
    Mark Zangardi
    Aditya Bardia
    Current Oncology Reports, 2019, 21